S. Nathan

S. Nathan, M. Belman, Z. Mohsenifar, 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Pitfalls in developing new compounds for idiopathic pulmonary fibrosis

F. Martinez, S. Nathan, 2017, Current opinion in pulmonary medicine.

Advanced Lung Disease and Lung Transplantation 2-1-2011 The HLA Class II Allele Allele DRB 1 * 15 is over-represented in patients with Idiopathic Pulmonary Fibrosis

I. Noth, G. Rosen, F. Sciurba, 2013 .

The HLA Class II Allele DRB1*1501 Is Over-Represented in Patients with Idiopathic Pulmonary Fibrosis

I. Noth, G. Rosen, F. Sciurba, 2011, PloS one.

The HLA Class II Allele DRB 1 * 1501 Is Over-Represented in Patients with Idiopathic Pulmonary Fibrosis

I. Noth, G. Rosen, F. Sciurba, 2011 .

Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms

D. Malide, J. Moss, S. Nathan, 2009, Proceedings of the National Academy of Sciences.

Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis.

S. Nathan, J. Belperio, O. Shlobin, 2008, Respiratory medicine.

Potential of imatinib mesylate as a novel treatment for pulmonary fibrosis

S. Nathan, O. Shlobin, M. Chhina, 2008, Expert review of respiratory medicine.

Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant

S. Nathan, A. Shorr, J. Wainright, 2007, European Respiratory Journal.

Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.

S. Nathan, O. Shlobin, S. Barnett, 2007, Chest.

Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.

S. Nathan, 2006, Clinics in chest medicine.

IDIOPATHIC INTERSTITIAL PNEUMONIA TO BIOPSY OR NOT TO BIOPSY: EMERGING INSIGHTS REGARDING AN AGE-OLD DILEMMA

C. Strange, S. Sahn, K. Leslie, 2005 .

Outcomes for patients with sarcoidosis awaiting lung transplantation.

S. Nathan, A. Shorr, D. Davies, 2002, Chest.

Lung Size Mismatch In Bilateral Lung Transplantation Is Associated With Allograft Function And Bronchiolitis Obliterans Syndrome

H. Fessler, S. Permutt, J. Orens, 2011, ATS 2011.

Contemporary optimized practice in the management of pulmonary sarcoidosis

S. Nathan, S. Aryal, 2019, Therapeutic advances in respiratory disease.

Bronchiolitis obliterans in single-lung transplant recipients.

J. Elashoff, S. Nathan, S. Shain, 1995, Chest.

Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry.

K. Flaherty, S. Nathan, C. King, 2020, Chest.

Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study.

F. Martinez, J. Behr, U. Müller-Lisse, 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

THE PATHOLOGIST'S APPROACH TO THE DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

Mayo, P. Grenier, G. Rosen, 2004 .

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

S. Orfanos, K. Flaherty, S. Nathan, 2022, Advances in Therapy.

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.

L. Edwards, S. Nathan, V. Tapson, 2021, The Lancet. Respiratory medicine.

A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis

G. Raghu, K. Flaherty, S. Nathan, 2020 .

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

H. Collard, F. Martinez, S. Nathan, 2019, The Lancet. Respiratory medicine.

Treatment of Pulmonary Hypertension in Interstitial Lung Disease

S. Nathan, C. King, 2017 .

Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?

H. Collard, F. Martinez, S. Nathan, 2017, Respiratory medicine.

Diseases that Mimic Idiopathic Pulmonary Fibrosis

S. Nathan, C. King, A. Brown, 2016 .

WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension

M. Humbert, S. Nathan, A. Wells, 2022, European Respiratory Review.

Pulmonary Hypertension in Sarcoidosis.

S. Nathan, R. Baughman, P. Engel, 2015, Clinics in chest medicine.

Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics

S. Nathan, A. Shorr, D. Helman, 2005, European Respiratory Journal.

Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases

S. Nathan, Whitney A. Brown, O. Shlobin, 2017, Chest.

Native lung complications in single-lung transplant recipients and the role of pneumonectomy.

S. Nathan, E. Lefrak, C. King, 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients.

B. Urban, S. Nathan, S. Barnett, 2003, Chest.

Prognosis, Clinical Course, and Monitoring of Patients with Idiopathic Pulmonary Fibrosis

S. Nathan, C. King, A. Brown, 2016 .

A Novel Concept in Idiopathic Pulmonary Fibrosis

K. Leslie, S. Nathan, O. Shlobin, 2015 .

Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.

R. D. du Bois, S. Nathan, L. Richeldi, 2012, American journal of respiratory and critical care medicine.

Sustained activation of toll-like receptor 9 induces an invasive phenotype in lung fibroblasts: possible implications in idiopathic pulmonary fibrosis.

S. Nathan, G. Jarai, G. Grant, 2015, The American journal of pathology.

Controversies in the Management of Pulmonary Hypertension in the Setting of Lung Disease

J. Barberà, S. Nathan, 2020 .

Pulmonary hypertension in chronic lung disease and hypoxia

F. Martinez, W. Seeger, J. Barberà, 2019, European Respiratory Journal.

Idiopathic non-specific interstitial pneumonitis responsive to transplant-associated immunosuppression.

S. Nathan, O. Shlobin, James P. Woodrow, 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns.

D. Badesch, S. Nathan, J. Stoller, 2010, Respiratory medicine.

Association of D-dimer and fibrinogen magnitude with hypercoagulability by thromboelastography in severe COVID-19

S. Djurkovic, S. Nathan, C. King, 2020, medRxiv.

Genetic determinants of risk and survival in pulmonary arterial hypertension

Lisa J. Martin, Ferhaan Ahmad, W. Ouwehand, 2018, bioRxiv.

The HLA Class II Allele Allele DRB 1 * 15 is over-represented in patients with Idiopathic Pulmonary Fibrosis

I. Noth, G. Rosen, F. Sciurba, 2017 .

Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19

S. Nathan, C. King, S. Aryal, 2021, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success

S. Nathan, C. King, A. Brown, 2020, Respiratory Care.

Cardiorespiratory Function Before and After Aerobic Exercise Training in Patients With Interstitial Lung Disease

L. Chan, S. Nathan, G. Connors, 2015, Journal of cardiopulmonary rehabilitation and prevention.

Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality

S. Nathan, C. King, O. Shlobin, 2016, Multidisciplinary Respiratory Medicine.

The Diagnosis and Management of Airway Complications Following Lung Transplantation

C. Channick, A. Mehta, S. Nathan, 2017, Chest.

Pulmonary Hypertension in Rare Parenchymal Lung Diseases

S. Nathan, O. Shlobin, 2017 .

Successful lung transplantation from a donor with a saddle pulmonary embolus.

S. Nathan, E. Lefrak, M. Guerrero, 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Evaluating new treatment options.

S. Nathan, 2017, The American journal of managed care.

Categorization and impact of pulmonary hypertension in patients with advanced COPD.

M. Gladwin, S. Nathan, R. Machado, 2010, Respiratory medicine.

Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?

P. Corris, S. Nathan, 2015, Thorax.

SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

S. Nathan, S. Barnett, N. Ad, 2005 .

Resequencing Study Con ﬁ rms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis

Ivana V. Yang, Brian E. Vestal, Camille M. Moore, 2019 .

Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis

J. Stauffer, S. Nathan, Ming Yang, 2021, Journal of clinical medicine.

The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis.

S. Nathan, C. King, A. Brown, 2020, Respiratory medicine.

Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.

S. Nathan, A. Zaiman, P. Hassoun, 2009, Chest.

High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success

S. Nathan, C. King, A. Brown, 2020, Respiratory Care.

Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.

S. Nathan, C. Denton, A. Fischer, 2016, Respiratory medicine.

sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.

R. Benza, S. Nathan, S. Mathai, 2017, Respiratory medicine.

Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases

S. Nathan, C. King, 2013, Current opinion in pulmonary medicine.

Lung transplantation in China: a firm foundation for a solid future

S. Nathan, S. Aryal, 2020, Annals of translational medicine.

S. Nathan, K. Ahmad, V. Khangoora, 2022, Cardiology clinics.

Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

N. Stockbridge, S. Nathan, M. Richter, 2022, Pulmonary circulation.

The 6-min walk test as a primary end-point in interstitial lung disease

S. Nathan, A. Wells, S. Harari, 2022, European Respiratory Review.

Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis.

S. Nathan, L. Lancaster, P. Ford, 2020, Contemporary clinical trials.

The influence of alternative instruction on 6-min walk test distance.

S. Nathan, O. Shlobin, A. Brown, 2013, Chest.

Ventilatory load characteristics during ventilatory muscle training.

K. Chon, S. Nathan, M. Belman, 1994, American journal of respiratory and critical care medicine.

Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment

S. Nathan, J. Behr, 2021, Current opinion in pulmonary medicine.

Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation

S. Nathan, O. Shlobin, 2012, European Respiratory Journal.

Pulmonary hypertension due to lung disease and/or hypoxia.

S. Nathan, P. Hassoun, 2013, Clinics in chest medicine.

Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients.

S. Nathan, S. Barnett, N. Burton, 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.

S. Nathan, S. Jordan, D. Ross, 1996, Chest.

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future

S. Nathan, 2019, American journal of respiratory and critical care medicine.

Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science

S. Nathan, P. Hassoun, 2016, European Respiratory Journal.

The Value and Application of the 6‐Minute‐Walk Test in Idiopathic Pulmonary Fibrosis

S. Nathan, Whitney A. Brown, 2018, Annals of the American Thoracic Society.

Pulmonary hypertension due to interstitial lung disease.

S. Nathan, C. King, 2019, Current opinion in pulmonary medicine.

Extracorporeal Membrane Oxygenation as a Bridge to Initial Medical Therapy in a Patient With Decompensated Pulmonary Arterial Hypertension Presenting With Biventricular Failure

S. Nathan, C. King, S. Aryal, 2019, Journal of medical cases.

Non-pharmacologic Management of Idiopathic Pulmonary Fibrosis

S. Nathan, C. King, A. Brown, 2016 .

Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis.

S. Nathan, A. Karlamangla, J. Belperio, 2008, Chest.

Parameters of donor-recipient size mismatch and survival after bilateral lung transplantation.

H. Fessler, S. Permutt, J. Orens, 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

S. Orfanos, K. Flaherty, S. Nathan, 2022, Advances in Therapy.

Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension

S. Nathan, C. King, Whitney A. Brown, 2017, Chest.

Pulmonary hypertension in patients with idiopathic pulmonary fibrosis

S. Nathan, V. Cottin, 2012 .

Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia

S. Nathan, C. King, D. Franco-Palacios, 2018, European Respiratory Journal.

Pulmonary Hypertension in Patients with Bronchiolitis Obliterans Syndrome Listed for Retransplantation

S. Nathan, O. Shlobin, S. Barnett, 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome.

J. Shelhamer, S. Permutt, J. Orens, 2012, Chest.

Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?

S. Nathan, C. King, O. Shlobin, 2017, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

Prognostic value of the 6min walk test in bronchiolitis obliterans syndrome.

S. Nathan, O. Shlobin, S. Barnett, 2009, Respiratory medicine.

Lung Transplantation for Pulmonary Hypertension

S. Nathan, S. Aryal, V. Khangoora, 2021, Reference Module in Biomedical Sciences.

Utility of inhaled pentamidine prophylaxis in lung transplant recipients.

S. Nathan, P. Zakowski, D. Ross, 1994, Chest.

Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation.

S. Nathan, O. Shlobin, S. Barnett, 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Single vs. bilateral lung transplantation: when and why

S. Nathan, S. Aryal, 2018, Current opinion in organ transplantation.

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

D. Brenner, J. Lachowicz, A. Gurney, 2020, PloS one.

Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations

S. Nathan, O. Shlobin, Shahzad Ahmad, 2012, Lung.

Sarcoidosis, race, and short-term outcomes following lung transplantation.

S. Nathan, A. Shorr, D. Helman, 2004, Chest.

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis

K. Flaherty, S. Nathan, V. Cottin, 2022, BMJ Open Respiratory Research.

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.

S. Nathan, R. Argula, V. Tapson, 2021, The New England journal of medicine.

Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study

M. Scholand, S. Nathan, A. Wells, 2021, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation.

S. Nathan, Edward M. Omron, S. Deb, 2006, Chest.

Mortality from Time of Listing for Transplantation as an Indicator of Candidate Outcomes

S. Nathan, A. Shorr, E. Lefrak, 2004 .

Mortality from time of listing for transplantation as an indicator of candidate outcomes.

S. Nathan, A. Shorr, E. Lefrak, 2004, Progress in transplantation.

Telesupport: just reach out and touch someone.

S. Nathan, S. Barnett, 2002, Chest.

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial

S. Nathan, V. Tapson, A. Waxman, 2021, American journal of respiratory and critical care medicine.

Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat?

S. Nathan, 2014, Thorax.

The soluble guanylate cyclase stimulator riociguat: Evidence in pulmonary hypertension and beyond

R. Benza, S. Nathan, S. Mathai, 2017 .

Clinical features and allograft failure rates of pulmonary antibody-mediated rejection categories.

P. Shah, J. Orens, K. Khush, 2022, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study.

G. Berry, P. Shah, J. Orens, 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Success of Educational Interventions on Pulmonary Arterial Hypertension Management

S. Nathan, N. Mehta, Chad Williamson, 2013 .

Organ Donors: Making the Most of What Is Offered.

S. Nathan, C. King, 2015, Chest.

IPF in Saudi Arabia: Lessons for all

S. Nathan, 2020, Annals of thoracic medicine.

POINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? Yes.

S. Nathan, 2020, Chest.

Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database

W. Seeger, J. Barberà, S. Nathan, 2021, Pulmonary circulation.

Dose modifications and dose intensity during treatment with pirfenidone

S. Nathan, M. Glassberg, L. Lancaster, 2016 .

Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture

S. Nathan, P. Macklin, Michael Getz, 2020, bioRxiv.

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease

M. Kreuter, S. Nathan, C. Moor, 2022, Respiratory Research.

Pulmonary hypertension due to fibrotic lung disease: hidden value in a neutral trial.

S. Nathan, Roberto G. Carbone, 2014, American journal of respiratory and critical care medicine.

Pulmonary complications of lung transplantation.

S. Nathan, O. Shlobin, Shahzad Ahmad, 2011, Chest.

Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19

S. Nathan, S. Dell’Orso, O. Shlobin, 2023, Science advances.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

J. Stauffer, S. Nathan, M. Wijsenbeek, 2017, European Respiratory Review.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

S. Nathan, M. Glassberg, W. Bradford, 2017, The Lancet. Respiratory medicine.

RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs

Thomas M. Blomquist, A. Levin, J. Willey, 2018, BMC Pulmonary Medicine.

F. Martinez, P. Corris, J. Egan, 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Aspergillus and endobronchial abnormalities in lung transplant recipients.

S. Nathan, A. Shorr, N. Burton, 2000, Chest.

Single‐center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients

S. Nathan, C. King, S. Aryal, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Drug Design, Development and Therapy Dovepress

S. Nathan, C. King, 2022 .

Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis

S. Nathan, V. Antony, M. Baz, 2011, European Respiratory Journal.

Curcumin induced oxidative stress attenuation by N-acetylcysteine co-treatment: a fibroblast and epithelial cell in-vitro study in idiopathic pulmonary fibrosis

S. Nathan, M. Chhina, G. Grant, 2019, Molecular medicine.

Resequencing Study Confirms Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Ivana V. Yang, Brian E. Vestal, Camille M. Moore, 2019, American journal of respiratory and critical care medicine.

Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury

M. Pirooznia, S. Nathan, I. Tunc, 2021, JCI insight.

Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension

Lisa J. Martin, Ferhaan Ahmad, W. Chung, 2019, Genome Medicine.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis

Lisa J. Martin, Keith A. Marsolo, Ferhaan Ahmad, 2018, bioRxiv.

Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension

Lisa J. Martin, Ferhaan Ahmad, W. Chung, 2019, Genome Medicine.

Lung Transplantation for Patients With COVID-19

A. Bharat, S. Nathan, C. King, 2021, Chest.

Prediction of minimal pressure support during weaning from mechanical ventilation.

S. Nathan, M. Belman, S. Koerner, 1993, Chest.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

R. Sussman, S. Sahn, S. Nathan, 2014, The New England journal of medicine.

Work of breathing after extubation.

S. Nathan, M. Belman, A. M. Ishaaya, 1995, Chest.

CHEST Recent Advances in Chest Medicine

S. Nathan, O. Shlobin, Shahzad Ahmad, 2010 .

Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4

S. Nathan, Margaret C. Emblom-Callahan, M. Chhina, 2018, Scientific Reports.

Pathogenesis of Idiopathic Pulmonary Fibrosis

S. Nathan, C. King, A. Brown, 2016 .

Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities

S. Nathan, C. King, S. Aryal, 2018, Respiratory Medicine.

Novel management strategies for idiopathic pulmonary fibrosis

S. Nathan, K. Ahmad, 2018, Expert review of respiratory medicine.

The Future for Idiopathic Pulmonary Fibrosis

S. Nathan, C. King, A. Brown, 2016 .

Predicting mortality in patients with sarcoidosis awaiting lung transplantation.

S. Nathan, A. Shorr, D. Davies, 2003, Chest.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials

Ami A. Shah, R. Hubbard, W. Dixon, 2013, Thorax.

Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome.

S. Nathan, N. Burton, J. Myers, 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Sanjiv J. Shah, M. Gladwin, G. Beck, 2017, American journal of respiratory and critical care medicine.

Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens

S. Nathan, M. Malicdan, S. El-Chemaly, 2021, Frontiers in Medicine.

Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β.

N. Isern, S. Nathan, P. Sime, 2012, American journal of respiratory and critical care medicine.

Supranormal expiratory airflow after bilateral lung transplantation is associated with improved survival.

S. Permutt, J. Orens, S. Nathan, 2011, American journal of respiratory and critical care medicine.

Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease.

S. Nathan, C. King, O. Shlobin, 2014, Respiratory medicine.

Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.

S. Nathan, C. King, 2017, The Lancet. Respiratory medicine.

Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

N. Stockbridge, S. Nathan, K. Antoniou, 2022, Pulmonary circulation.

IPF clinical trial design and endpoints

S. Nathan, K. Meyer, 2014, Current opinion in pulmonary medicine.

Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

S. Nathan, C. King, 2014, Drug design, development and therapy.

Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension.

L. Chan, S. Nathan, A. Weinstein, 2013, Respiratory medicine.

Comorbidities of advanced lung disease.

S. Nathan, J. Nations, 2009, The Mount Sinai journal of medicine, New York.

Improved Six-Minute Walk Distance and Cardiorespiratory Fitness in Patients With Pulmonary Arterial Hypertension Following an Intensive Exercise Program

L. Chan, S. Nathan, G. Connors, 2011 .

Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications

S. Nathan, C. King, J. Collen, 2012, Current Respiratory Care Reports.

The Pulmonary Fibrosis Foundation Patient Registry: Rationale, Design, and Methods.

I. Noth, G. Raghu, J. Stauffer, 2020, Annals of the American Thoracic Society.

Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry

G. Raghu, J. Stauffer, C. Spino, 2018, Idiopathic interstitial pneumonias.

The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.

S. Birring, M. Scholand, S. Nathan, 2022, Respiratory medicine.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis

S. Nathan, A. Wells, M. Glassberg, 2019, Chest.

Pulmonary Hypertension and Interstitial Lung Disease

S. Nathan, R. Baughman, Roberto G. Carbone, 2017, Springer International Publishing.

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.

S. Sahn, R. D. du Bois, S. Nathan, 2015, Respiratory medicine.

Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.

S. Nathan, L. Lancaster, K. Meyer, 2015, Chest.

Changes in fatigability following intense aerobic exercise training in patients with interstitial lung disease.

L. Chan, S. Nathan, G. Connors, 2015, Respiratory medicine.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

S. Sahn, R. D. du Bois, S. Nathan, 2014, American journal of respiratory and critical care medicine.

Idiopathic pulmonary fibrosis trials: recommendations for the jury

R. D. du Bois, S. Nathan, 2011, European Respiratory Journal.

Pulmonary hypertension in interstitial lung disease

S. Nathan, 2008, International journal of clinical practice. Supplement.

SEVERE PULMONARY HYPERTENSION IN IDIOPATHIC PULMONARY FIBROSIS

S. Nathan, A. Shorr, C. Lettieri, 2006 .

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

J. Stauffer, S. Nathan, M. Glassberg, 2019, Advances in Therapy.

Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

H. Collard, G. Raghu, J. Behr, 2013, Annals of Internal Medicine.

Riociguat for Sarcoidosis Associated Pulmonary Hypertension: Results of a One Year Double Blind, Placebo Controlled Trial.

S. Nathan, R. Baughman, O. Shlobin, 2021, Chest.

Inhaled Treprostinil Dose in Pulmonary Hypertension Associated with Interstitial Lung Disease and Its Effects on Clinical Outcomes.

S. Nathan, C. King, V. Tapson, 2022, Chest.

A Randomized, double-blind, placebo-controlled study to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) at a dose of 30 mcg/kg-IBW/hr (iNO 30) in subjects at risk of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF) receiving Oxygen Therapy.

G. Raghu, K. Flaherty, S. Nathan, 2020, Chest.

Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)

S. Nathan, M. Glassberg, W. Bradford, 2016 .

Pirfenidone is Efficacious in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Mild Restrictive Disease

S. Nathan, D. Spirig, M. Glassberg, 2016 .

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

R. D. du Bois, S. Nathan, A. Wells, 2016, Thorax.

Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry

M. Scholand, S. Nathan, A. Wells, 2020, European Respiratory Journal.

Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease

S. Nathan, C. King, O. Shlobin, 2018, European Respiratory Journal.

Serial Development of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis

K. Leslie, S. Nathan, O. Shlobin, 2008, Respiration.

Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension

S. Nathan, C. King, S. Aryal, 2021, Pulmonary circulation.

Transesophageal echocardiographic assessment of pulmonary venous flow after single lung transplantation.

G. Maurer, R. Siegel, S. Nathan, 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary Hypertension

Jonathan H. Chung, S. Nathan, P. Hassoun, 2023, Pulmonary circulation.

Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study.

Jonathan H. Chung, D. Lynch, F. Martinez, 2019, The Lancet. Respiratory medicine.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

S. Birring, M. Scholand, S. Nathan, 2018, Respiratory medicine.

Elevated cell‐free DNA in respiratory viral infection and associated lung allograft dysfunction

H. Valantine, P. Shah, J. Orens, 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).

P. Shah, J. Orens, K. Khush, 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation

S. Quake, G. Berry, H. Valantine, 2019, EBioMedicine.

Comparison of donor‐derived cell‐free DNA between single versus double lung transplant recipients

G. Berry, P. Shah, K. Khush, 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis.

G. Berry, M. Pirooznia, H. Valantine, 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation

W. Gahl, S. Nathan, I. Rosas, 2018, PloS one.

Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury.

H. Valantine, P. Shah, J. Orens, 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Utility of a Molecular Classifier as a Complement to HRCT to Identify Usual Interstitial Pneumonia.

Jonathan H. Chung, D. Lynch, G. Raghu, 2020, American journal of respiratory and critical care medicine.

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.

M. Kramer, S. Nathan, A. Wells, 2020, The Lancet. Respiratory medicine.

Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis.

S. Nathan, O. Shlobin, S. Barnett, 2010, Respiratory medicine.

Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.

S. Nathan, T. Maher, P. Thuresson, 2017, Journal of managed care & specialty pharmacy.

Multimodal noninvasive prediction of pulmonary hypertension in IPF

S. Nathan, A. Brown, S. Barnett, 2019, The clinical respiratory journal.

Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease

M. Scholand, N. Kolaitis, K. Flaherty, 2022, Chest.

Connective tissue disease-associated interstitial lung disease and outcomes after hospitalization: A cohort study.

S. Nathan, K. Ahmad, A. Brown, 2019, Respiratory medicine.

Dental Personnel Treated for Idiopathic Pulmonary Fibrosis at a Tertiary Care Center — Virginia, 2000–2015

S. Nathan, K. Cummings, J. Cox‐Ganser, 2018, MMWR. Morbidity and mortality weekly report.

Computed Tomography Findings Suggestive of Connective Tissue Disease in the Setting of Usual Interstitial Pneumonia

Jonathan H. Chung, S. Montner, S. Nathan, 2021, Journal of computer assisted tomography.

Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life

B. Reeve, N. Kolaitis, S. Nathan, 2021, Pulmonary circulation.

Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants.

Jong Sun Park, E. Silverman, H. Collard, 2023, American journal of respiratory and critical care medicine.

Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository

A. Levin, J. Willey, P. Massion, 2016, BMC Pulmonary Medicine.

Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial.

R. Davey, S. Nathan, C. King, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study

I. Noth, M. Scholand, K. Flaherty, 2020, BMC Pulmonary Medicine.

Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation.

S. Nathan, O. Shlobin, S. Barnett, 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.

S. Nathan, C. King, 2016, Chest.

A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.

G. Raghu, K. Flaherty, S. Nathan, 2021, Annals of the American Thoracic Society.

Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis

K. Brown, S. Nathan, O. Shlobin, 2011, Respirology.

Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis

A. Remaley, S. Nathan, M. Kaler, 2021, European Respiratory Journal.

Making a Confident Diagnosis of Obliterative Bronchiolitis

S. Nathan, A. Brown, 2013 .

Outcomes of COPD lung transplant recipients after lung volume reduction surgery.

S. Nathan, S. Barnett, L. Edwards, 2004, Chest.

Surgical Lung Biopsy for Interstitial Lung Disease: Safety and Feasibility at a Tertiary Referral Center.

H. Mani, S. Nathan, C. King, 2020, Annals of the American Thoracic Society.

THE IMPACT OF INHALED TREPROSTINIL ON PATIENT LUNG FUNCTION: RESULTS FROM THE INCREASE STUDY

L. Edwards, S. Nathan, V. Tapson, 2020 .

Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease.

S. Nathan, 2023, American journal of respiratory and critical care medicine.

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

S. Nathan, R. Argula, V. Tapson, 2023, European Respiratory Journal.

A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma.

S. Nathan, M. Stylianou, M. Roth, 2017, The Journal of allergy and clinical immunology.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials

S. Nathan, M. Glassberg, W. Bradford, 2016 .

Nebulized medications for the treatment of dyspnea: a literature review.

S. Nathan, P. Fine, S. Connor, 2015, Journal of aerosol medicine and pulmonary drug delivery.

ARTEMIS-IPF: A Placebo-Controlled Trial Of Ambrisentan In Idiopathic Pulmonary Fibrosis

F. Martinez, G. Raghu, J. Egan, 2012, ATS 2012.

Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.

S. Nathan, T. Maher, F. Dejonckheere, 2017, Journal of managed care & specialty pharmacy.

The Six-Minute Walk Test in Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry

S. Birring, M. Scholand, S. Nathan, 2020, A102. ILD DIAGNOSIS AND MONITORING.

Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging

Jonathan H. Chung, M. Strek, S. Montner, 2021, Journal of clinical medicine.

Lung Transplantation of COVID-19 Patients

A. Bharat, S. Nathan, C. King, 2021, Chest.

PULMONARY HYPERTENSION IN IDIOPATHIC PULMONARY FIBROSIS: EPIDEMIOLOGY AND CLINICAL CORRELATES

S. Nathan, A. Shorr, D. Helman, 2005 .

Differential soluble interleukin-2R levels in bilateral bronchoalveolar lavage after single lung transplantation.

A. Marchevsky, S. Nathan, S. Jordan, 1994, The Journal of Heart and Lung Transplantation.

Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

H. Collard, G. Raghu, J. Behr, 2013, Annals of Internal Medicine.

Considerations when Selecting Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients with Pulmonary Hypertension: A Narrative Review.

M. Kosinski, S. Nathan, S. Mathai, 2022, Chest.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

R. D. du Bois, S. Nathan, M. Glassberg, 2016, BMJ Open Respiratory Research.

Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis

S. Nathan, C. King, J. Pastre, 2022, Thorax.

CMV Infection Following mRNA SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients

S. Nathan, C. King, S. Aryal, 2022, Transplantation direct.

Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

H. Collard, G. Raghu, J. Egan, 2013, Annals of Internal Medicine.

Antacid therapy and idiopathic pulmonary fibrosis: cause for heartburn?

S. Nathan, 2016, The Lancet. Respiratory medicine.

DOSE RESPONSE ANALYSIS OF INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND ITS EFFECTS ON CLINICAL WORSENING

S. Nathan, A. Gerke, V. Tapson, 2021, Chest.

RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia

H. Collard, F. Martinez, J. Behr, 2017 .

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials

Ami A. Shah, R. Hubbard, W. Dixon, 2013, Thorax.

Curcumin induced oxidative stress attenuation by N-acetylcysteine co-treatment: a fibroblast and epithelial cell in-vitro study in idiopathic pulmonary fibrosis

S. Nathan, G. Grant, S. Bui, 2019, Molecular Medicine.

Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.

R. D. du Bois, S. Nathan, O. Shlobin, 2011, Chest.

Classification Models of Idiopathic Pulmonary Fibrosis Patients

N. Diawara, S. Nathan, M. Kaler, 2020 .

Comorbidities of advanced lung disease.

S. Nathan, J. Nations, 2009, The Mount Sinai journal of medicine, New York.

Lung transplantation: disease-specific considerations for referral.

S. Nathan, 2005, Chest.

Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.

S. Nathan, C. Denton, A. Fischer, 2016, Respiratory medicine.

Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension.

L. Chan, S. Nathan, A. Weinstein, 2013, Chest.

Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real‐world patient data repository

S. Nathan, L. Lancaster, H. Farber, 2023, Pulmonary circulation.

Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis

H. Collard, N. Thakur, S. Nathan, 2021, Thorax.

STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF)

J. Golden, S. Nathan, N. Kolatkar, 2019, Idiopathic interstitial pneumonias.